Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-05-26T22:03:59.539Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of early use of long acting paliperidone (1 and 3 monthly) in a first-episode psychosis sample

Published online by Cambridge University Press:  13 August 2021

P. Gil Lopez ,
J.M. Rodriguez ,
L. Garcia Fernandez ,
E. Fernandez Martin ,
N. Fernandez Gayoso  and
V. Sanchez Estevez
P. Gil Lopez*
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
J.M. Rodriguez
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
L. Garcia Fernandez
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
E. Fernandez Martin
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
N. Fernandez Gayoso
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
V. Sanchez Estevez
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Relapse prevention is a key objetive for patients with a First Episode Psychosis (FEP) and the low adherence to antipsychotic (AP) treatment is the main reason for relapse after a FEP.

Objectives

There are no clear recommendations about the early use of long-acting injectables (LAIs) in FEP. We review the impact on hospitalization rates of the early use (earlier than 1 year after the inclusion in our Early Intervention Service “Lehenak”) of LAI paliperidone in a FEP sample.

Methods

We evaluated in a naturalistic study a sample (N=384) of patients with a FEP. We carried out a mirror-design study to compare the numer of hospitalizations before and after the introduction of LAI paliperidone (1 and 3 monthly) in early users (<1 year) vs late users (>1 year).

Results

A total of 384 FEP patients with LAI paliperidone were assessed.

Early Paliperidone LAI (n=201)Late Paliperidone LAI (n=173)Within groups comparisons t (p)
Hospitalizations pre-LAI mirror period (media, standard deviation)1.76 (1.97)2.22 (2.60)1,87 (0.06)
Days in hospital pre-LAI mirror period21.42 (28.28)28.02 (38.27)1.87 (0.06)
Hospitalizations post-LAI mirror period0.68 (1.61)0.80 (1.74)0.73 (0.46)
Days in hospital post-LAI mirror period15.17 (40.58)18.78 (45.24)0.81 (0.42)

Conclusions

There was no difference between the early and late introduction of LAI Paliperidone in the number of hospitalizations after treatament. There was a trend to present more previous hospitalizations and days in hospital in late users. This could support an earlier use of paliperidone LAI to prevent an excess of hospitalizations due to late introduction.

Disclosure

The presenting author has received honouraria for lectures or advisory boards from Janssen, Otsuka, Lundbeck and Angelini in the last five years.

Keywords

outcomeRelapsefirst-episode psychosislong-acting paliperidone
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S811
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.